Heat waves against cancer: new trial tests hyperthermia for rectal tumors
NCT ID NCT07372300
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 3 trial tests whether adding modulated electro-hyperthermia (mEHT) to standard treatment helps shrink locally advanced rectal cancer. About 126 adults will receive either standard therapy alone or with mEHT twice a week for six weeks. The goal is to see if the heat-based treatment improves tumor down-staging and complete response rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
modulated electro-hyperthermia (mEHT) using the Oncotherm EHY-2030 device
What this could lead to
If it works, this could offer a way to shrink rectal tumors more effectively before surgery, potentially improving outcomes and reducing recurrence.
What could go wrong
This is a mid-stage trial with only 126 participants, so results may not apply broadly. The added hyperthermia could cause discomfort or skin burns, and it may not improve response over standard therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dalin Tzu Chi Hospital
RECRUITINGChiayi City, Dalin Township, 600401, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact